AI-Designed Lung Drug Shows Promise in Slowing Biological Aging

Key points

• Rentosertib, developed by Insilico Medicine using AI, is being tested for idiopathic pulmonary fibrosis (IPF).
• In a 12-week phase 2a trial with 42 IPF patients, six proteomic aging clocks indicated a biological age reduction of 3-4 years on average, with one case showing up to 6 years.
• The strongest effects were observed after four weeks in patients taking 30 mg twice daily.
• Researchers compared results with data from 55,000 UK Biobank participants, finding that the drug reversed certain age-associated protein changes.
• The study acknowledges limitations, including the small sample size and the difficulty of separating aging effects from anti-fibrotic disease treatment.
• Side effects were described as manageable, including mild diarrhea, lower potassium levels, and temporary liver enzyme increases.

Background

This development follows a broader trend in longevity research where drugs for age-related diseases are being evaluated for their potential to modulate aging itself. Previous studies have explored how metabolic interventions, such as specific amino-acid diets or cholesterol transport blockers, might influence healthspan and disease progression. The current focus on proteomic clocks represents a shift from epigenetic models, aiming for more direct mechanistic insights into biological aging.

How outlets are covering it

Fox News emphasizes the 'bonus' of anti-aging effects and quotes Insilico Medicine’s Alex Zhavoronkov on the potential for extending life as a human right. The New York Times highlights the role of AI in drug design and the use of 'aging clocks' to predict morbidity. Nature provides a detailed methodological perspective, noting that while six proteomic clocks agreed on lower biological age, they cannot fully disentangle aging from disease-specific effects, and suggests that the 30 mg twice-daily dose showed more consistent aging reversal than the dose with the greatest respiratory improvement. FirstWord PHARMA was inaccessible due to a JavaScript challenge.

Why it matters

If confirmed, rentosertib could represent a significant step in dual-purpose drug development, targeting both a specific disease and the underlying mechanisms of aging. This could lead to therapies that not only treat conditions like IPF but also improve overall healthspan and reduce the risk of other age-related diseases. However, the preliminary nature of the findings means that larger trials are necessary to determine if these effects translate to real-world longevity and health benefits.

What to watch

Insilico Medicine is conducting a phase 3 trial in China with over 300 patients to further evaluate rentosertib’s efficacy and safety. Future studies will need to include healthy older adults and populations without IPF to isolate the drug’s anti-aging effects from its anti-fibrotic activity. Researchers are also planning to adjust dosages based on side effect profiles to allow for longer treatment durations.